Innovative Medicines Initiative (IMI 2)

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.276 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.

IMI was launched in 2008 and currently has 46 ongoing projects, with more in the pipeline. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects

Giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. IMI warmly encourages small and medium-sized enterprises (SMEs), medium-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.

 

Presentations from the IMI stakeholder Forum, held on 17-18.10.2017

 

IMI Success Stories

 

 

IMI2 Call 8: Next deadlines 

 

Next cut-off  date for IMI2 Ebola+ call for proposals:  15/3/2018

For more information

 

 

IMI2 Call 13 - Future topics :

Find projects partners: Search for project partners via the Partner Search Tool: http://www.imi.europa.eu/content/partner-search

IMI homepage

IMI newsletter

IMI FAQs

IMI Annual Implementation Plan

 Presentations from the IMI Stakeholder Forum 2015

 

Documents:

 

  IMI 2 Call 9 - call text
  IMI 2016 Activity Report
  Webinar presentation on Data quality in preclinical research and development
  Webinar presentation on Development of immune tolerance therapies for the treatment of rheumatic diseases
  Webinar presentation on Next generation of electronic translational safety – NEXGETS
  Webinar presentation on IMI2 Rules and Procedures
  Webinar presentation on Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD)
  Webinar presentation on Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform
  Webinar presentation on Joint influenza vaccine effectiveness studies - JIVES
  Proposal Template
  SUMMARY OF THE MOST RELEVANT PROVISIONS FOR PARTICIPATING IN IMI2 ACTIONS
  Model Grant Agreement
  Manual for submission, evaluation and grant agreement
Jump to page content